Last update 27 Feb 2026

ACAM-Flu-A

Overview

Basic Info

Drug Type
Therapeutic vaccine, Genetically engineered subunit vaccine
Synonyms
ACAM FLU A
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Infectious DiseasesRespiratory Diseases
Active Indication-
Inactive Indication
Influenza A virus infectionInfluenza, Human
Originator Organization
Acambis PlcAcambis Plc
Active Organization-
Inactive Organization
Vlaams Instituut voor Biotechnologie - Flanders InstituteVlaams Instituut voor Biotechnologie - Flanders InstituteSanofiSanofiAgenus, Inc.Agenus, Inc.
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with ACAM-Flu-A
NCT00819013
/ CompletedPhase 1
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Reactogenicity, and Immunogenicity of Recombinant M2e Influenza-A Vaccine Candidate ACAM FLU-A) in Healthy Adults
100 Clinical Results associated with ACAM-Flu-A
Login to view more data
100 Translational Medicine associated with ACAM-Flu-A
Login to view more data
100 Patents (Medical) associated with ACAM-Flu-A
Login to view more data
100 Deals associated with ACAM-Flu-A
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 1
United States
SanofiSanofi
01 Jul 2007
Influenza A virus infectionPhase 1-
Vlaams Instituut voor Biotechnologie - Flanders InstituteVlaams Instituut voor Biotechnologie - Flanders Institute
-
Influenza A virus infectionPhase 1-
Agenus, Inc.Agenus, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT00819013 (FLU-A, CTgov)
Phase 1
Influenza, Human
87
Alhydrogel+ACAM-FLU-A
(ACAM-FLU-A Adjuvanted With Alhydrogel)
nzhrrsefha = sbkxfmpykf yrrliowypd (ztdvxmqokl, ushysjtbrc - hsxajervde)
View more
-
16 Jan 2012
(ACAM-FLU-A Adjuvanted With Stimulon® QS-21)
nzhrrsefha = eekcyuzacd yrrliowypd (ztdvxmqokl, yvysxzwpmd - ntgougmeji)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free